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Abstract  
The idiopathic inflammatory myopathies are a heterogeneous group of disorders 
characterised by diffuse muscle weakness and inflammation.  A common 
immunopathogenic mechanism is the cytokine driven infiltration of immune cells into the 
muscle tissue. Recent studies have dissected further the inflammatory cell types and 
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associated cytokines involved in the immune-mediated myopathies and other chronic 
inflammatory and autoimmune disorders.   In this review we outline the current knowledge 
of cytokine expression profiles and cellular sources in the major forms of inflammatory 
myopathy and detail the known mechanistic functions of these cytokines in the context of 
inflammatory myositis. Furthermore, we discuss how the application of this knowledge may 
lead to new therapeutic strategies for the treatment of the inflammatory myopathies, in 
particular for cases resistant to conventional forms of therapy.  
Introduction  
The idiopathic inflammatory myopathies are a heterogeneous group of autoimmune muscle 
disorders that have been classified into the following major types on the basis of their 
distinct clinical and pathological features and underlying immunopathogenic mechanisms: 
polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM) and immune-
mediated necrotising myopathies (IMNM).  Other subtypes include overlap syndromes and 
cancer-associated myositis [1, 2] An autoimmune origin for these conditions is supported by 
immune cell mediated myocytotoxicity, the presence of autoantibodies and overexpression 
of MHC class I and II molecules in myositis tissue [3-6]. However, there is still debate as to 
whether IBM is primarily autoimmune in origin or a degenerative myopathy with associated 
inflammatory features and an immune component. 
A shared pathogenic mechanism in these diseases is the infiltration of muscle tissue by a 
variety of activated immune cells, a process that is heavily dependent on the presence of 
multiple cytokines [7, 8]. Key cellular sources of these cytokines include regenerating 
myocytes within myositis muscle, cells from the adaptive immune response (CD4+ and CD8+ A
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T cells, macrophages, dendritic cells and B cells) and cells from the innate immune system 
such as mast cells and gamma delta T cells [1, 9-11].  
The overexpression of TNF, IFN-γ and IL-12 in the blood and muscle tissue of patients with 
various types of myositis has implicated the Th1 response as a key mediator of pathogenesis 
in these diseases [12]. However, more recent studies detailing the presence of Th17 related 
cytokines such as IL-17, IL-22 and IL-6 have highlighted an alternative pathogenic 
mechanism and provided additional targets for therapy [13, 14]. In addition to their pro-
inflammatory actions, these cytokines can also display anti-inflammatory properties and 
show duality of function depending on their concentrations, the local inflammatory milieu 
and the expression of co-stimulatory and adhesion molecules [15]. In addition a number of 
cytokines (such as IL-1α and IL-17) may also exert direct effects on the muscle tissue [13, 
16]. These include the activation of signalling pathways such as NF-κB, further amplifying 
the inflammatory response through upregulation of MHC-I expression and 
cytokine/chemokine production. Activation of NF-κB by pro-inflammatory cytokines can also 
have negative effects, inhibiting myocyte migration and differentiation, and may thereby 
impair muscle regeneration and repair [17].  
In this review we will summarise the current understanding of key cellular sources of 
proinflammatory cytokines within myositis tissue and expression profiles amongst the 
different inflammatory myopathies.  We also outline the multiple actions of these cytokines 
in the context of inflammatory myositis. Furthermore, we discuss the implications of these 
observations for the identification of novel therapeutic targets and development of new 
cytokine-based therapies for the treatment of resistant cases of IIM.  
Immunopathogenesis of inflammatory myopathies A
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While the different inflammatory myopathies share a number of common characteristics, 
including muscle weakness and inflammation, each type has distinct clinical and 
pathological features [18]. The underlying immunopathogenic mechanisms also differ and 
the available evidence indicates that in PM and IBM a CD8+ T cell mediated mechanism is 
primarily involved, whereas in DM and IMIM a humorally driven immune process is 
implicated [4, 18-20].  Although a number of autoantibodies have been identified (Table 1), 
their roles are uncertain and the specific antigenic targets of the immune response are still 
largely unknown, with the exception of a subgroup of cases of IMIM associated with  
antibodies to the signal recognition particle (SRP) and 3-hydroxymethyl glutaryl coenzyme A 
reductase (HMGCR) which are thought to be involved in the pathogenesis of the myositis.  In 
addition, there has been increasing recognition of the importance of non-immune 
mechanisms such as the possible contribution of MHC- I expression to muscle dysfunction 
and damage through induction of endoplasmic stress and the unfolded protein response[21, 
22] It is also recognised that immature myogenic cells involved in muscle regeneration may 
activate TLR pathways leading to cytokine and chemokine production in addition to their 
role in antigen presentation, and may also be a target of the immune response[16, 21, 22].  
 
 
 
Polymyositis and inclusion body myositis 
In PM and IBM there is a mixed endomysial mononuclear inflammatory infiltrate comprising 
CD8+ T cells, macrophages and myeloid dendritic cells (Table 1).  CD8+ cells surround and A
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invade non-necrotic muscle fibres [23] and are thought to cause perforin-mediated 
cytotoxic injury as a result of the interaction between autoantigen presenting MHC class I 
molecules on muscle fibres and co-stimulatory molecules on CD8+ cells [19]. The invading 
mononuclear cells also include CD68+ macrophages and BDCA-1+ myeloid dendritic cells 
which are jointly thought to contribute to the cytotoxic injury and necrosis of muscle fibres 
[3, 24]. The infiltrating cells in polymyositis (and dermatomyositis) also include a population 
of apoptosis-resistant CD8+ and CD4+ T cells lacking the CD28 ligand (CD8+CD28-/-, 
CD4+CD28-/-) which are also thought to be cytotoxic effector cells [25].  Studies employing T 
cell receptor spectratyping on muscle tissue and blood have shown that CD8+ T cells are 
clonally expanded in situ and persist over time and during relapses of disease in PM, while in 
IBM which has a much more protracted clinical course there is evidence that epitope 
spreading may occur with time [26-28]. In IBM, in contrast to PM, there is increased 
expression of βAPP and cell stress proteins and accumulation of amyloid proteins, and 
muscle fibres undergo progressive autophagic degeneration and atrophy [29].  There is 
evidence from studies of muscle biopsies as well as in vitro studies that this process may be 
secondary to the effects of pro-inflammatory cytokines such as IL-1β [30] . 
 
 
 
Dermatomyositis 
In DM the inflammatory infiltrate comprises primarily CD4+ T cells, macrophages and small 
numbers of B cells and plasma cells, and is mainly perivascular and perimysial in distribution A
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[31].  In addition, BDCA-2+ plasmacytoid dendritic cells, which secrete type 1 interferons, 
are present in the perimysium and endomysium (Table 1) [32]. The immune response is 
thought to target the endothelium of capillaries and small blood vessels leading to 
activation of the complement pathway and deposition of C5b-9 membrane attack 
complexes, with resulting depletion of capillaries and muscle ischaemia [3, 4]. Deposition of 
immunoglobulins on intramuscular capillaries is postulated to activate the complement 
cascade, triggering the production of pro-inflammatory cytokines and chemokines which 
cause increased expression of adhesion molecules on endothelial cells and further 
recruitment of immune cells [3].  Although antibodies reacting with a number of ubiquitous 
autoantigens have been identified in DM [20, 33] , endothelial cell specific antibodies have 
as yet not been reported (Table 1). 
Immune-mediated necrotising myopathies 
The IMNMs are a heterogeneous group of myopathies which as a group they are 
characterised by a relative paucity or even absence of inflammatory changes in muscle 
tissue [34]. However, in some cases CD68+ macrophages are prominent in the endomysium 
and perimysium, and small numbers of CD4+ and CD8+ T cells and B cells may also be 
present (Table 1) [35].  In addition, there is diffuse expression of MHC-I antigens in muscle 
fibres, particularly in cases associated with statin therapy [36] or antibodies to HMGCR [37, 
38], SRP or tRNA aminoacyl synthetases [34, 35]. This finding is in keeping with an immune-
mediated process in which muscle fibres participate in antigen presentation to the immune 
system.  The complement pathway has also been implicated in IMNM, as shown by the 
presence of the membrane attack complex on muscle fibres in cases associated with anti-A
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SRP or antisynthetase antibodies [35] and evidence of complement dependent antibody-
mediated cytotoxicity in cases with anti-SRP antibodies [39].  
 
Myositis Specific Autoantibodies  
Circulating antibodies to a number of ubiquitous autoantigens occur with variable 
frequencies in PM, DM and overlap syndromes and have more recently also been identified 
in IBM and IMNM (Table 1) [30-34].  The most prevalent is the group of antisynthetases, 
including anti-Jo-1 (anti-histidyl tRNA synthetase), which is present in about 20% of cases of 
PM and DM and is a marker for the antisynthetase syndrome[36, 37]. In DM, antibodies to 
Mi-2 which is a component of the nucleosome remodelling deacetylase complex, have a 
high specificity especially for the adult form of the disease [39, 40] and a number of other 
autoantibodies targeting MDA-5, NXP-2, SAE 1/2 and TIF-1α/γ have specificities for different 
subgroups of DM cases [31]. There is increasing recognition that in addition to being 
potential biomarkers for different subgroups of inflammatory myopathy, some myositis-
specific antibodies such as anti-Jo-1 and anti-Mi-2 may also have a role in the induction and 
maintenance of the autoimmune process as a result of over-expression of the target 
antigens in regenerating muscle fibres as part of the repair process in muscle [33, 40, 41].   
 
 
 
Current Concepts in Cytokine Functioning  
Cytokines are small secreted proteins that regulate the immune response and play a major 
role in T cell differentiation and specialisation and modulation of immune cell function. The A
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release of cytokines from immune cells can be induced directly by immunoglobulin- or 
complement-receptor mediated signalling or by the activation of a wide variety of cellular 
receptors by pathogen components. One family of such receptors, the Toll-like receptors 
(TLRs), play a crucial role in mediating inflammation by inducing cytokine release upon 
engagement of the receptor by an appropriate ligand, a process that is normally tightly 
regulated by a number of regulatory factors including microRNAs (miRNAs)[42, 43] .  In 
muscle activation of the TLR-3 pathway in human myoblasts induces production of IFN-β, 
which has also been shown to be expressed in myositis muscle tissue in immature muscle 
fibres which may be a target of the immune response [43].  
 
 
Traditionally cytokines were divided into classes on the basis of their known function, that is 
pro-inflammatory vs anti-inflammatory/regulatory [15]. However, increasing evidence 
demonstrates that a number of pro-inflammatory cytokines can have both stimulatory and 
inhibitory effects on immune cells, a phenomenon dependent on the concentration of 
cytokine present, the local immune milieu and the influence of other interacting cells and 
molecules [15, 44]. A key example of this is TGF-β, previously only considered to be an 
immune suppressor cytokine because of its role in the development and differentiation of 
regulatory T cells (T-regs). The recent identification of Th17 cells has also implicated TGF-β 
in pro-inflammatory responses due to its role in Th17 differentiation and function [45]. 
Interestingly, recent studies have shown that the presence of pathogens or inflammatory 
mediators such as IL-6 and IL-1 can induce conversion of T-regs to Th17 cells and a switch in 
cytokine profiles.  Furthermore a number of studies have demonstrated that in the presence A
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of IL-12 and/or TNF-α Th17 cells can be converted into non-classic Th1 cells which secrete 
both IFN-γ and IL-17.  In comparison, differentiated Th1 and Th2 cells are stably expressed 
and prevented from converting to alternative T effector phenotypes associated with the 
reciprocal lineage. Differentiation of T-helper-cell subsets is controlled by lineage specifying 
transcription factors that bind to regulatory elements in genes encoding cytokines and other 
transcription factors. Acetylation and methylation of histone molecules at the promoter and 
enhancer region of genes dictates the expression of genes associated with one T helper 
effector phenotype and the suppression of those associated with other lineages [46].  
Nearly two decades ago, patients with rheumatoid arthritis were successfully treated with 
the first monoclonal antibody targeting TNF-α [47]. Since then intensive research efforts 
have been focused on key cytokines such as IL-1, IL-6, IL-12 and IL-17 and the targeting of 
these molecules therapeutically in a variety of inflammatory and autoimmune diseases [15, 
45]. It is being increasingly recognised that cytokines do not act in isolation but function 
within a milieu of multiple cytokines with the ability to synergize with or antagonize one 
another’s functional capacity [44, 48]. For example, in vitro studies examining the combined 
effects of TNF-α, IL-1β and IL-17 demonstrated enhanced activation of inflammatory 
signalling pathways in comparison to the individual cytokines alone. Furthermore, a number 
of pathways not activated by the individual cytokines alone were activated in the presence 
of the combined cytokines [49, 50].  This highlights the importance of investigating 
combination therapies or developing therapeutic strategies that will modulate multiple 
inflammatory pathways in the treatment of chronic inflammatory and autoimmune diseases 
[44, 51].   
Key Cytokines in Myositis  A
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Overexpression of cytokines within DM, PM, IBM and IMNM muscle tissue is thought to 
contribute to a number of common immunopathogenic mechanisms in the inflammatory 
myopathies; co-stimulation, immune cell activation, and transmigration of inflammatory 
cells into the muscle fibres (Figure 1). Furthermore, cytokines can act directly on the muscle 
fibres, leading to the synthesis of soluble pro-inflammatory mediators thus contributing to 
the persistence of the inflammatory response [19]. The study of cytokine expression within 
myositis muscle began in 1986 with the identification of IL-2 and the interferons α, β and γ 
in PM tissue [7].  
Since then extensive research has characterised a wide variety of cytokines expressed in the 
different inflammatory myopathies (Table 2) and their functional effects. Cytokine profiling 
has been carried out both in muscle tissue and skin, in addition to blood and serum analysis 
for systemic expression.  
Muscle tissue 
Investigation of cytokine expression in myositis initially began with immunohistochemical 
studies of muscle tissue. As a method for cytokine detection, immunohistochemistry is 
hampered by the low concentrations of cytokines within the tissue, their transient 
expression and issues of sensitivity and specificity [7]. As a result, a number of research 
groups turned their focus to the examination of cytokine mRNA transcripts in muscle tissue 
[52]. These studies showed strong expression of inflammatory cytokines in all myositis 
subtypes with the majority suggesting a Th1 response [7, 53]. The application of gene 
expression array technology to myositis research has led to the identification of additional 
immune cells and pathways within inflammatory myopathy muscle tissue [52].  A
cc
ep
te
d 
A
rti
cl
e
11 
This article is protected by copyright. All rights reserved. 
Such gene array studies have identified a prominent type I interferon genetic signature in 
DM muscle in comparison with other forms of myositis [54, 55]. However, expression of 
interferon α and β and their inducible genes is not exclusively specific to DM and also occurs 
in PM [1, 55], and PM patients have shown responsiveness to anti-IFN-α therapy [56, 57]. 
Furthermore pDCs, a major source of IFN-α, have been identified in the muscle tissue of 
patients with PM and IBM in addition to DM [52]. A similar pattern of expression of IL-1α,   
IL-1β and TGF-β has also been demonstrated across DM, PM and IBM tissue. In particular an 
enhanced IL-1α expression in the endothelial cells has been noted in DM, PM and IBM tissue 
highlighting these cells as a key pro-inflammatory cytokine source [7, 58].  
The key Th1 cytokine IFN-γ has been detected in the muscle tissue of all the major subtypes 
of inflammatory myopathy [7, 35]. IFN-γ and two other Th1 cytokines, IL-1β and TNF-α were 
found to be markedly increased in IBM muscle compared to PM and DM tissue [30]. 
Additionally, the IFN-γ signalling pathway has been demonstrated to be upregulated in the 
invaded versus non-invaded muscle fibres in IBM tissue [59]. A strong relationship between 
degeneration-associated markers and the expression of IFN-γ, IL-1β and TNF was mainly 
observed in IBM muscle tissue compared to PM and DM [30]. The Th1 response through 
IFN-γ secretion leads to the induction of M1 macrophages which results in further tissue 
damage [9].IMNM previously described as an immune myopathy with a limited 
mononuclear cell infiltrate has also been shown to display a strong M1/Th1 response within 
the muscle tissue [35].   
Traditionally a Th1 response was considered to be a predominant driver of disease in the 
inflammatory myopathies. However the discovery of IL-17 and the Th17 lineage has drawn 
attention to the role of IL-17 signalling in the pathogenesis of myositis. Increased IL-17 A
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mRNA and protein expression has been demonstrated in DM, PM and IBM muscle tissue 
[13]. One study in PM and DM patients indicated a Th17 mediated pathway in patients who 
were responsive to IVIG therapy [60]. Another Th17 cytokine IL-22 has also been detected in 
PM, DM and IBM tissue and found to co-express with a proportion of IL-17 cells [61, 62]. IL-
22 was also found to correlate with disease activity in PM and DM patients [61]. 
Furthermore IL-22 mRNA expression was downregulated in DM patients who responded 
clinically to IVIG therapy whereas IBM patients who were clinical non-responders showed no 
change in IL-22 expression [62].  
 
The novel cytokine ‘TNF-like weak inducer of apoptosis’ (TWEAK) which is a member of the 
TNF superfamily and its receptor FGF –inducible molecule-14 (Fn14) have been implicated in 
the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple 
sclerosis. TWEAK has been shown to synergize with Th17 polarizing cytokines to enhance IL-
17 production by Th17 cells and blockade of the TWEAK receptor FN14 suppresses Th17 
differentiation [63]. More recently the TWEAK/Fn14 axis has also been implicated in 
myositis and muscle atrophy [64, 65]. Enhanced TWEAK-Fn14 mRNA and protein expression 
was demonstrated in IBM muscle, in contrast to PM and DM. Furthermore, siRNA inhibition 
of TWEAK expression restored myogenic differentiation in IBM and DM via inhibition of the 
NF-кB pathway [64].  
Th2 cytokines such as IL-4 and IL-13 are significantly overexpressed in IBM and PM tissue in 
comparison to DM and healthy controls [7, 66, 67]. On the other hand, a Th2 cell infiltrate in 
DM muscle has been associated with a lower severity of disease [67]. This is possibly due to 
the generation of M2 macrophages by Th2 cytokines leading to tissue repair[9]. This is in A
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contrast with the view that DM is a humorally mediated disease whereby Th2 cells would 
drive B-cell maturation and differentiation into autoantibody producing plasma cells, further 
exacerbating microvascular damage. Furthermore, there is higher expression of 
immunoglobulin genes in the muscle of IBM and PM patients in comparison to DM [32, 62, 
68]. By contrast there is a more prominent IFN-inducible gene signature in DM in 
comparison to the other subtypes [62, 69]. 
The cytokines TGF-β and IL-10 are traditionally considered to be anti-inflammatory, however 
as discussed earlier in this review cytokines can display both pro - and anti-inflammatory 
properties depending on the context. Enhanced TGF-β mRNA expression has been observed 
in both DM and IBM muscle and following IVIG treatment a decrease in expression was 
observed in DM but not IBM [62, 70]. Overexpression of IL-10 mRNA in PM, IBM and DM 
muscle in comparison to non-myositic tissue has also been demonstrated. Again, a decrease 
in expression was observed in DM but not IBM tissue following IVIG therapy [43, 71]. The 
downmodulation of TGF-β and IL-10 following IVIG treatment in DM suggests a key role for 
these molecules in DM pathogenesis but not IBM.  
Skin   
Skin involvement is a unique characteristic of DM that distinguishes it from the other 
inflammatory myopathies. The pathogenesis of skin inflammation in DM is less well 
characterized than in muscle. Gene microarray analysis demonstrated an IFN signature in 
DM skin although this study did not assign this as being “type I” or “type II”[72]. An in vitro 
study comparing muscle - and skin - derived T cells demonstrated differential cytokine 
production between the two tissue types. Higher levels of IL-4 and IFN-γ were secreted by 
muscle derived T cells compared to skin derived T cells and the ratio of IL-4/ IFN-γ was A
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associated with severity of muscle injury. Conversely, skin derived T cells produced higher 
amounts of IL-17A than muscle derived T cells [67]. Furthermore, an additional study 
demonstrated an enhanced mast cell infiltrate in juvenile DM skin in comparison to paired 
muscle tissue [73]. Overexpression of TGF-β mRNA has been described in the endomysial 
connective tissue of DM muscle and associated with fibrosis of the skin [62, 74]. Conversely 
a depletion of TGF-β, IL-10 and FoxP3 positive cells has been demonstrated in DM skin 
suggesting depletion of Treg cells and associated cytokines is a key factor in the 
pathogenesis of the skin changes [74, 75].  
Blood/Serum  
Similar to studies in muscle tissue, gene expression profiling of peripheral blood 
mononuclear cells and whole blood has identified a type 1 interferon signature in both DM 
and PM. This type 1 interferon profile was found to reflect disease activity in both DM and 
PM patients highlighting its potential as a possible biomarker [54, 76-79]. The serum levels 
of IFN-α were found to be significantly higher in DM, PM and IMNM patients compared to 
IBM.  Serum profiling of IBM highlighted a strong Th1 profile and flow cytometry analysis 
confirmed this and showed a diminished Treg population [12]. 
The IL-1β and TNF-α gene pathways have been shown to be activated in a subset of PM 
patients [80]. Both cytokines have been shown to inhibit myoblast and myotube 
differentiation and TNF-α has been shown to directly inhibit the expression of the myogenic 
microRNAs; miR1, -133, and -206 which are heavily involved in skeletal muscle 
differentiation and maintenance [43].  
The IL-17 gene signature was found to be enhanced in subsets of DM and PM patients over 
the type I interferon profile. Significantly higher levels of IL-17 and the Th17 polarizing A
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cytokine IL-23 are produced by activated PBMCs from early stage DM and PM in comparison 
to samples from more established disease [13]. In DM patients the percentage of circulating 
Th17 cells correlated positively with serum levels of creatine kinase which is an indicator of 
severity of muscle injury. In comparison, Th17 cells were negatively correlated with the 
expression of the myogenic microRNA miR-206 [81]. No significant differences in IL-17 
serum levels have been demonstrated between the different inflammatory myopathy 
subtypes [12, 13]. However in DM patients IL-17 serum levels were strongly correlated with 
IFN gene expression and IFN-regulated chemokine levels [82]. Enhanced expression of the 
Th17 polarizing cytokines (IL-6, IL-1β, TGF-β and IL-23) has also been demonstrated in DM 
patients in comparison to healthy controls [81].  
Therapeutic Implications  
The current treatment strategy for patients with immune mediated inflammatory 
myopathies involves first line treatment with corticosteroids, alone or in combination with 
an immunosuppressant such as methotrexate, azathioprine or mycophenolate, and in more 
resistant cases intravenous immunoglobulin or biologic therapy [4, 83-85]. B cell depletion 
with Rituximab (anti-CD20), which interferes with autoantibody production as well as 
cytokine production and antigen presentation to T cells is a very promising option, 
particularly for resistant cases of dermatomyositis [86-89]. The TNFα inhibitors etanercept 
and infliximab have shown varying responses in the treatment of DM and PM, with some 
cases showing no response [90-95], and lack of response in IBM [83, 90]. 
Immunomodulation with IFN-β has also been shown to be ineffective in IBM, but may be 
beneficial in some cases associated with chronic viral infection [96, 97]. Information 
regarding the efficacy of biologic therapy in trials involving myositis patients is limited.  A
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Furthermore, interpretation of study results is restricted by the study size and duration [84, 
98, 99]. Treatment options are further confounded by reported cases of exacerbation or 
onset of myositis, or malignancy following treatment with TNFα inhibitors [83]. The results 
of these studies highlights the need for new therapeutic targets and treatment strategies. 
The dissection of CD4+ T effector cell types within inflammatory and autoimmune disorders 
has focused drug discovery efforts on the associated cytokines of each T effector cell subset.  
Traditionally, CD4+ Th1 cells or CD8+ cytotoxic T cells have been considered the main players 
in the inflammatory myopathies. Increasingly it is being recognized that a heterogeneous 
inflammatory infiltrate exists within the inflamed myositis muscle and specific T cell 
phenotypes are not exclusive to an individual disease subset [25]. The three major subsets 
of T helper cells Th1, Th2 and Th17 are all inhibited by Abatacept (CTLA4-Ig) which blocks 
the signals required for T cell-activation (Figure 2). A number of case studies describing the 
successful treatment of patients with DM and PM by Abatacept have been reported. To 
date however a clinical trial of Abatacept has not been completed [100-102].  
Inhibition of IL-6, a key Th17 polarising cytokine, by Toculizumab has demonstrated efficacy 
in patients with refractory polymyositis [103]. A clinical trial for assessing Toculizumab in 
resistant DM and PM has been registered, however recruitment has not been initiated 
(NCT02043548). Toculizumab may also be a suitable candidate for treatment of IBM as 
evidenced by enhanced IL-6 expression in IBM patients particularly those resistant to 
immunosuppressive therapy [71].   
Blockade of IL-1 signalling using anakinra has also resulted in clinical responses in myositis 
patients [104-107]. In a number of these patients  IL-17 signalling was indirectly targeted 
through the reduction of IL-1 dependent Th17 differentiation [104]. Ustekinumab an A
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approved anti-IL-23/IL-12p40 antibody suppresses both Th1 and Th17 responses. 
Monoclonal antibodies targeting the IL-23p19 subunit which inhibits Th17 responses are 
currently in development.  Overexpression of both IL-12 and IL-23 has also been observed in 
myositis patients yet these therapies have not been assessed in the context of myositis [12, 
13]. 
Targeting Th17 differentiation upstream is advantageous over direct IL-17 targeting as 
blocking Th17 responses abrogates not just IL-17 but also IL-22 and IFN-γ. These cytokines 
have been found to be co-expressed by Th17 and other IL-17 secreting cell types [61, 108].  
Clinical trials of pharmacological inhibitors directly targeting IL-17 and its receptor are 
currently in progress for the treatment of a number of other autoimmune diseases [13, 14]. 
Direct IL-17 inhibition is yet to be assessed in myositis and warrants clinical trials in patients 
with resistant PM and DM, as well as cases of IBM which as a group respond poorly to 
conventional forms of immune therapy.  
 
 
 
Conclusions 
The introduction of biologics therapy almost twenty years ago revolutionised the treatment 
of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis by broadening 
the number of treatment options available. Advances in recent years leading to the 
identification of additional effector immune cell subsets and their associated cytokine 
pathways as outlined in this review have led to the development of an increasing number of A
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monoclonal antibodies for clinical use, the most noteworthy being therapies targeting the 
Th17-IL-17 inflammatory axis. There holds great promise for the application of these 
therapies to the inflammatory myopathies in particular for patients who respond poorly to 
current treatments. However, to date there have been few clinical trials and the application 
of biologics in myositis has lagged behind its use in other autoimmune diseases. Controlled 
trials of sufficient size and duration are warranted to provide sufficient information and 
enable the introduction of additional therapies to the current repertoire.  
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Figure Legends 
 
Figure 1:  Immune effector cells and associated cytokines in myositis.  
CD4+ and CD8+ T cells are activated by autoantigen expressing APCs. Activated CD4+ T cells 
differentiate into the various T-helper effector cells.  Th1 and Th17 cells secrete cytokines 
that mediate muscle damage and inflammation and the activation of additional immune 
cells. Th2 and Tfh cells modulate B cell function and differentiation into antibody producing 
plasma cells leading to complement mediated capillary damage. The presence of Treg cells 
reduces inflammation and tissue damage by inhibiting CD4+ and CD8+ effector T cells. A 
degree of plasticity can also occur in these cell types Th17 -> Th1 and Th17 <-> Treg. APC: 
antigen presenting cell; MHC: major histocompatibility complex; Th: T – helper cell; Treg: T 
regulatory cell; CTL: cytotoxic T lymphocyte; CD28 -/-:CD28 null T lymphocyte; M1: type 1 
macrophage (pro-inflammatory); M2: type 2 macrophage (anti-inflammatory).  
 
Figure 2:  Putative cytokine targets in myositis and available blocking monoclonal 
antibodies.  
IL-17RA and IL-17RC represent the A and C chains of the IL-17 receptor; IL-1R: Interleukin 1 
receptor; TFG-βR: TFG-β receptor; IL-23R: IL-23 receptor; IL-6R: IL-6 receptor 
 A
cc
ep
te
d 
A
rti
cl
e
26 
This article is protected by copyright. All rights reserved. 
Table 1. Idiopathic Inflammatory myopathies 
IM Subtype Muscle biopsy Cellular infiltrate Associated Autoantibodies
  
References 
Dermatomyositis Perimysial and perivascular 
inflammation; perifascular 
atrophy; MAC deposition; 
MHC-I and II expression 
CD4+ T cells; macrophages;      
B cells; Plasma cells; BDCA-
2+ plasmacytoid dendritic 
cells; CD8+CD28-/- and 
CD4+CD28n-/- T cells; mast 
cells; γ/∆ T cells 
Anti-Mi 2 
Anti-TIF1y 
Anti-MDA5/Anti-CADM-140 
Anti-NXP-2 
Anti-SAE 
 
[3, 10, 11, 25, 31, 33, 109-
111] 
Polymyositis Endomysial inflammation; 
MHC-I and II expression 
CD8+ T cells; macrophages; 
myeloid dendritic cells; 
CD68+ macrophages; 
BDCA-1+ myeloid dendritic 
cells; CD8+CD28-/- and 
CD4+CD28n-/- T cells; mast 
cells;  γ/∆ T cells 
Anti-tRNA synthetases  
(e.g. anti-Jo) 
Anti-SRP 
[3, 10, 11, 24, 25, 110, 111] 
Inclusion body myositis   Endomysial inflammation; 
rimmed vacuoles; protein 
aggregation, inclusions; 
MHC-I and II expression 
CD8+ T cells; macrophages; 
myeloid dendritic cells; 
CD68+ macrophages; 
BDCA-1+ myeloid dendritic 
cells 
Anti-cN1A [3, 24, 25, 110, 111] 
Immune-mediated 
necrotizing myopathies  
Endomysial and perimysial 
inflammation; MAC, MHC-I 
expression 
CD68+ macrophages; few 
CD4+, CD8+T cells, B cells 
Anti-HMGCR 
Anti-SRP 
Anti-tRNA synthetases  
 
[35-38, 110] 
 
Adapted and modified from Dimachkie MM. Idiopathic inflammatory myopathies. Journal of neuroimmunology 2011; 231:32-42. 
A
cc
ep
te
d 
A
rti
cl
e
27 
This article is protected by copyright. All rights reserved. 
 
Table 2. Sources of key cytokines in the inflammatory myopathies (IM) 
Cytokines IM subtypes Serum Mononuclear cells Endothelial cells Muscle  ECM Skin References 
Th1         
IFN-γ All + + - DM, PM, IBM - DM [7, 12, 35, 53, 59, 108] 
IL-2 All + DM, PM, IBM - DM, PM, IBM - DM [7, 12, 35, 53] 
IL-12 All + + - + - - [7, 12, 35, 53] 
TNF-α All + + - + - - [7, 12, 30, 53, 80] 
Th2    -     
IL-4 All + DM - + - DM [7, 12, 66, 67] 
IL-13 All + - - - - DM [7, 12, 66, 67] 
Th17    -     
IL-17 All + + - DM, PM, IBM - DM [12, 13, 60, 67, 82] 
IL-22 DM, PM - + PM + - - [13, 61, 62] 
IL-23 DM, PM - + - + - - [13, 81] 
IL-6 All + DM, PM, IBM - DM, PM, IBM - - [12, 13, 81] 
TWEAK DM, PM, IBM - DM, PM, IBM - DM, PM, IBM - - [63, 64] 
T-reg         
IL-10 DM, PM, IBM + + - DM, PM, IBM - - [7, 12, 43, 74, 75] 
TGF-β DM, PM, IBM - DM DM, PM, IBM DM, PM, IBM DM DM [7, 58, 62, 70, 74, 75, 81] 
IL-1 family          
IL-1α DM, PM, IBM - DM, PM, IBM DM, PM, IBM DM, PM, IBM - - [7, 12, 58] A
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IL-1β All All DM, PM, IBM - DM, PM, IBM - - [7, 12, 30, 58, 80] 
Type I IFNs         
IFN-α All + DM, PM, IBM - DM - DM [1, 7, 12, 32, 54, 57, 62, 69, 
112] 
IFN- β DM, PM + DM, PM, IBM - DM,PM - DM [1, 7, 32, 54, 62, 69, 71] 
 
Adapted and modified from Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory 
myopathies. Muscle & Nerve 2003; 28:659-82. All refers to DM, PM, IBM, IMNM 
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